CA2396350A1 - Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique - Google Patents

Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique Download PDF

Info

Publication number
CA2396350A1
CA2396350A1 CA002396350A CA2396350A CA2396350A1 CA 2396350 A1 CA2396350 A1 CA 2396350A1 CA 002396350 A CA002396350 A CA 002396350A CA 2396350 A CA2396350 A CA 2396350A CA 2396350 A1 CA2396350 A1 CA 2396350A1
Authority
CA
Canada
Prior art keywords
ser
cnrasgef
leu
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396350A
Other languages
English (en)
Inventor
Daniela Rotin
Youngshil Pak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Priority to CA002396350A priority Critical patent/CA2396350A1/fr
Priority to AU2003250685A priority patent/AU2003250685A1/en
Priority to PCT/CA2003/001130 priority patent/WO2004011018A2/fr
Publication of CA2396350A1 publication Critical patent/CA2396350A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
CA002396350A 2002-07-31 2002-07-31 Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique Abandoned CA2396350A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002396350A CA2396350A1 (fr) 2002-07-31 2002-07-31 Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique
AU2003250685A AU2003250685A1 (en) 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists
PCT/CA2003/001130 WO2004011018A2 (fr) 2002-07-31 2003-07-31 Procedes d'identification selective d'antagonistes de recepteur beta-1-adrenergique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002396350A CA2396350A1 (fr) 2002-07-31 2002-07-31 Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique

Publications (1)

Publication Number Publication Date
CA2396350A1 true CA2396350A1 (fr) 2004-01-31

Family

ID=30774592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396350A Abandoned CA2396350A1 (fr) 2002-07-31 2002-07-31 Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique

Country Status (3)

Country Link
AU (1) AU2003250685A1 (fr)
CA (1) CA2396350A1 (fr)
WO (1) WO2004011018A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802775B1 (fr) 2004-09-14 2010-05-26 The Regents of the University of Colorado Procédé de traitement faisant intervenir du bucindolol fondé sur le ciblage génétique
CN112575051A (zh) * 2019-09-27 2021-03-30 泰州医药城国科化物生物医药科技有限公司 一种β1肾上腺素受体的细胞筛选模型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203776B1 (en) * 1997-04-03 2001-03-20 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability
CA2259830A1 (fr) * 1999-01-20 2000-07-20 Hsc Research And Development Limited Partnership Activateur ras de molecules d'acide nucleique, proteines et procede d'utilisation

Also Published As

Publication number Publication date
WO2004011018A3 (fr) 2004-05-06
AU2003250685A8 (en) 2004-02-16
WO2004011018A2 (fr) 2004-02-05
AU2003250685A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
Ferguson Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling
Clancy et al. Pertussis-toxin-sensitive Gα subunits selectively bind to C-terminal domain of neuronal GIRK channels: evidence for a heterotrimeric G-protein-channel complex
US6521414B2 (en) Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
Pak et al. Direct binding of the β1 adrenergic receptor to the cyclic AMP-dependent guanine nucleotide exchange factor CNrasGEF leads to Ras activation
JP2008500266A (ja) Ａｍｐａ受容体エンドサイトーシスの阻害剤を用いた神経細胞反応のモジュレート方法
EP1131351A2 (fr) Peptides modulant l'interaction des ephrines de classe b avec les domaines pdz
Malhotra et al. Molecular biology of protein kinase C signaling in cardiac myocytes
Kramer et al. Antagonists of cyclic nucleotide-gated channels and molecular mapping of their site of action
KR20090007374A (ko) 신경변성 질환과 알츠하이머병을 치료하고 정상 기억을 향상시키기 위한 방법과 조성물
Pani et al. Unique Positive Cooperativity Between the β-Arrestin–Biased β-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β2-Adrenergic Receptor
JP2001504681A (ja) 蛋白質相互作用の阻害
WO2006007422A2 (fr) Compositions et methodes liees a la phosphorylation des canaux calciques par camkii
CA2396350A1 (fr) Methodes pour l'identification selective d'antagonistes de recepteurs .beta.-1-adrenergique
US20100210521A1 (en) Compositions and methods for modulating ampa receptor-mediated excitotoxicity
EP2671889B1 (fr) Peptides dérivés de rf-amide et procédés associés
US20020143164A1 (en) Ras activator nucleic acid molecules, polypeptides and methods of use
JP4326326B2 (ja) Ｅｐｆ受容体アッセイ、化合物および治療用組成物
US6790608B2 (en) Methods of identifying and ADP-glucose receptor ligand, agonist or antagonist
US9062285B2 (en) Compositions and methods for modulating AMPA receptor-mediated excitotoxicity
Zhang Functional studies of kisspeptin analogues and the human kisspeptin receptor
US20040072275A1 (en) Interaction of NMDA receptor with protein tyrosine phosphatase
WO2004016646A2 (fr) Modulateurs peptidiques d'un sous-type de pyruvate kinase m2 (m2-pk) specifique de tumeurs
Strachan P90 Ribosomal S6 Kinase 2 (RSK2) Directly Phosphorylates the 5-HT2A Serotonin Receptor thereby Modulating Signaling
WO2013102264A1 (fr) Compositions et méthodes de modulation de l'excitoxicité médiée par les récepteurs ampa
McLean Ligand regulation of β1-and β2-adrenergic receptors and their GFP-tagged forms

Legal Events

Date Code Title Description
FZDE Dead